Tyra Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Trading Arrangements:
Rule 10b5-1 Trading Plans
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2025, our officers and directors took the following actions with respect to such trading arrangements:
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares Authorized to be Sold*** · Expiration Date | |||||
| Todd HarrisPresident, Chief Executive Officer and Director | Terminate (1) | 11/21/2025 | X | 315,000 | 12/31/2026 |
| Alan FuhrmanChief Financial Officer | Terminate (2) | 11/21/2025 | X | 80,000 | 7/31/2026 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.
(1) Trading arrangement was originally adopted on 11/4/2024.
(2) Trading arrangement was originally adopted on 11/5/2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.